

Big data analytics and Al for precision medicine.


BIG DATA FOR PRECISION MEDICINE SYMPOSIUM NCSR DEMOKRITOS, Athens 11 July 2018

Dr. Andreas Persidis

CEO, Biovista Inc. & President, Hellenic BioCluster


Changing landscape of healthcare





Data is the new oil









Where is the value? data or model?



MIT Technology

Log in / Create an account Search C

7l Subscribe





Business Impac

Facebook may stop the data leaks, but it's too late: Cambridge Analytica's models live on



flags about the amount of data being collected because of Kogan's academic credentials, and now claims that he deceived people at Facebook about his intents.

However, though Cambridge Analytica built profiles of 30 million US voters, its central goal wasn't to craft ads targeted at *those* people. Rather, the models it built from that much smaller cohort of 270,000 quiz-takers would allow an advertiser to create proxy profiles of much larger collections of *similar* people on Facebook. This capability is what enabled the company to craft ads precisely targeted at small groups of voters based on personality traits. And it continues to exist even after the original data is deleted.


The method

Kogan's technique—emulating an innovation by psychology researchers at the Cambridge Psychometrics Centre, particularly Michal Kosinski and David Stillwell—was to use a scientifically validated psychology quiz

Healthcare: a special kind of problem







multiple interdependencies & feedback/forward loops

Artificial Intelligence - present day limits



University of Pittsburgh Medical Center Predict 30-day all cause readmissions across pediatric patients at discharge

79% accuracy

Computer Assisted Diagnosis (CAD) spotted 52% of the cancers as much as a year before the women were officially diagnosed





Identified hypothyroidism as an unknown risk factor for statin patients developing diabetes.

Financial Trading - Marketing Personalization - Fraud Detection - Engineering optimizations - Recommendations - Search - Self-driving Cars



cure for cancer



Ō



Comorbidities



ion drive

Problems with ML/DL/GAN



Bias


Black box – trust

Overfitting - Context?

Artificial General Intelligence

The problem of bias





Husky classified as wolf



Explanation for classification



Tesla drives into left lane barrier

Shotgun shell: Google's AI thinks this turtle is a rifle


https://www.theguardian.com/technology/2017/nov/03/googles-ai-turtle-rifle-mit-research-artificial-intelligence

"Why Should I Trust You?" Explaining the Predictions of Any Classifier MT Ribeiro, S Singh, C Guestrin https://arxiv.org/pdf/1602.04938

Undesirable correlations in the training data are hard to detect yet can influence the performance of many ML/DL systems.



The challenge of Artificial *General* Intelligence (AGI)



... but how are the individual Als *combined* to create the AGI? Are they simply "added"? Are they executed in some "sequence"?

© Biovista Inc. 2018. All rights reserved.

Share my data?... no thank you.





Pharma is setting 2 ML system objectives




Federarted

Privacy Preserving




Cycle of Discovery

Value-based view of "expertise"



Process-based view of "expertise"






Hellenic Biocluster





to innovate to collaborate to deliver



GATEWAY TO THE **GREEK LIFE SCIENCES** HEALTHCARE COMMUNITY

HBio profile



Who we are

- The first biosciences cluster in Greece.
- Established in 2006, by an initial group of 8 companies and the PRAXI Network, the technology transfer arm of the Foundation for Research & Technology- Hellas (FORTH).

Industry-led structure

- Greek knowledge-intensive biosciences companies
- Strong R&D focus.
- International business outlook

Some Statistics



Biotech and Pharma

11

Diagnostics

7

Medtech

3

Specialist Services

14

Academic Research organisations


9

Top Research centers as Associate members



Top Bioscience research centers with activities in basic & translational research.

Support HBio companies through the development of creative research & development partnerships, and the provision of access to state-of-the art facilities and specialized services.













External Relations













Policy making for new Programmes

HBIO Flagship Projects



- International interest
- Realistic for Greece
- Real interest of stakeholders
- Contribute to positioning of Greek biopharma industry

Thank you

andreasp@biovista.com

© Biovista Inc. 2017. All rights reserved.